title: Management of metastatic malignant melanoma of the bladder.
abstract: Recombinant interleukin-2 (IL-2) has demonstrated antitumor activity and durable clinical responses in patients with metastatic melanoma. Careful screening and selection of appropriate patients has improved the safety profile of IL-2 administration. Gross hematuria would ordinarily preclude the safe delivery of IL-2. We report a case of metastatic melanoma to the bladder presenting with hematuria. A complete resection was performed and subsequently allowed the administration of high-dose, bolus IL-2. The combination of resection and IL-2 therapy resulted in a partial response maintained for more than 18 months. Symptomatic bladder melanoma should be aggressively treated to allow for systemic immunotherapy, which can provide durable responses.
authors.affiliation: Laboratory of Tumor Immunology and Biology, National Cancer Institute, Bethesda, Maryland, USA.
authors.forename: Christopher S D
authors.initials: CS
authors.lastname: Lee
authors.forename: Ian K
authors.initials: IK
authors.lastname: Komenaka
authors.forename: Karl S
authors.initials: KS
authors.lastname: Hurst-Wicker
authors.forename: Gail
authors.initials: G
authors.lastname: Deraffele
authors.forename: Josephine
authors.initials: J
authors.lastname: Mitcham
authors.forename: Howard L
authors.initials: HL
authors.lastname: Kaufman
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D000075202:Contraindications; D006417:Hematuria / Q000601:surgery; D006801:Humans; D007376:Interleukin-2 / Q000627:therapeutic use; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000556:secondary* / Q000601:surgery; D008875:Middle Aged; D012878:Skin Neoplasms / Q000473:pathology; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000556:secondary* / Q000601:surgery
chemical_list: D000970:Antineoplastic Agents; D007376:Interleukin-2